<DOC>
	<DOC>NCT00420056</DOC>
	<brief_summary>This is a pilot study evaluating tumor activity using Positron Emission Tomography, which is also known as a "PET scan". This study will assess the safety of using PD-0332991 in patients with mantle cell lymphoma.</brief_summary>
	<brief_title>An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Histologically documented MCL. Must have received at least one prior therapy. Eastern Cooperative Oncology Group (ECOG) performance status â‰¤1. Adequate organ function as outlined in the protocol. Major surgery, radiation therapy, or systemic therapy within 4 weeks of study enrollment. Prior radiation therapy to &gt;25% of the bone marrow (whole pelvis is 25%). Uncontrolled brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>